The activity of AMG 811 was assessed in a phase I RCT comparing AMG 811 therapy with placebo in DLE patients, showing changes in biomarkers associated with IFNγ in the blood and skins of DLE patients. The gene discussed is IFNG; the disease is discoid lupus erythematosus.